$12.040
-0.020 (-0.17%)收盘时
INFU 资讯
INFU 事件
Sees 2026 Adjusted EBITDA Margin in Mid to Low 20%'s
Still sees 2026 adjusted EBITDA margin in the mid to low 20%'s.
Company Reports Q2 Revenue of $36.9M
Reports Q2 revenue $36.9M, consensus $36.35M. CEO Carrie Lachance commented, "We delivered another strong quarter, achieving record revenue of $36.9M and growing Adjusted EBITDA by 7.6%. Our Oncology business continued its steady momentum, surpassing $20M in quarterly revenue for the first time, while Wound Care delivered exceptional growth driven by strong adoption of our new lymphedema compression therapy offerings...Behind the scenes, we made meaningful progress optimizing our new ERP platform, laying the foundation for greater scalability, efficiency, and long-term productivity improvements across the organization. Looking ahead, we remain focused on disciplined execution, delivering 6% to 8% pro forma revenue growth in 2026, maintaining strong EBITDA margins, and creating long-term value for our shareholders."
InfuSystem Approves $20M Stock Repurchase Program
InfuSystem announced that the company's Board of Directors has approved a stock repurchase program authorizing the company to repurchase up to $20M of the company's outstanding common stock starting on July 1, 2026 and running through June 30, 2028. The program will supersede the previous authorization which is set to expire on June 30, 2026. Under the current authorization, the company repurchased approximately 1.6M shares of stock for approximately $11.9M though March 31, 2026. Repurchases will be made through open market purchases, private transactions, or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. Carrie Lachance, Chief Executive Officer of InfuSystem, said, "This authorization carries on the Company's established buyback policy which we have used when appropriate to enhance shareholder value. I believe the stock repurchase program demonstrates our confidence in being able to continue to execute with discipline, deliver profitable growth and drive long term value for the rest of 2026 and beyond. It also reflects the strength of our balance sheet and cash flows. Our top priority for use of capital remains making strategic investments that position the Company for sustainable growth, although this program provides us with the flexibility to be opportunistic in repurchasing shares when valuations become attractive."
Q1 Revenue at $33.7M, Below Consensus
Reports Q1 revenue $33.7M, consensus $34.35M. CEO Carrie Lachance commented, "Overall, we delivered a solid quarter that reflects both disciplined execution and meaningful strategic progress. While GAAP revenue declined modestly year over year to $33.7M, that decline was expected and resulted from the strategic decision to restructure our GE Healthcare biomedical services contract. On a pro-forma basis, net revenue grew 1.7%, and just as importantly, profitability held strong. We delivered $6.4M of Adjusted EBITDA, essentially flat year over year, due to margins improving to 18.9%. The restructuring reduced Q1 revenue by $1.6M, but it enabled a significantly larger reduction in direct contract expenses. While GAAP revenue is lower, the economics of the business are better, and that's clearly showing up in our Adjusted EBITDA performance. On March 1, 2026, after nearly two years of intense preparation, we successfully went live on our new ERP system. I would call this transformational...the ERP gives us a scalable platform to support future growth. We're already identifying enhancements that offer fast payback and high returns."
InfuSystem Trading Resumes
InfuSystem trading resumes
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。